Literature DB >> 21916609

Pharmacokinetic allometric scaling of oligonucleotides.

Iftekhar Mahmood1.   

Abstract

The objective of this study was to evaluate the predictive performance of interspecies scaling of oligonucleotides to predict clearance and volume of distribution at steady state in humans from animal data. The human pharmacokinetic parameters were predicted using 1, 2, or at least 3 animal species. The results of the study indicated that the pharmacokinetic parameters of oligonucleotides can be predicted with reasonable accuracy in humans when at least 3 animal species are employed. On the other hand, allometric scaling based on 1 or 2 species or fixed coefficient or fixed exponent can be erratic and unreliable. Further work should be conducted in this direction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21916609     DOI: 10.1089/nat.2011.0299

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  5 in total

1.  Pharmacokinetic Time Course Scaling of a Subcutaneously Administered Pegylated Peptide Conjugate for a First-in-Human Investigation.

Authors:  Elliot Offman; Andrea N Edginton
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

2.  Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2'-o-(2-methoxyethyl) modifications.

Authors:  Rosie Z Yu; John S Grundy; Scott P Henry; Tae-Won Kim; Daniel A Norris; Jennifer Burkey; Yanfeng Wang; Andrew Vick; Richard S Geary
Journal:  Mol Ther Nucleic Acids       Date:  2015-01-20       Impact factor: 10.183

3.  A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.

Authors:  Konstantinos Biliouris; Puneet Gaitonde; Wei Yin; Daniel A Norris; Yanfeng Wang; Scott Henry; Robert Fey; Ivan Nestorov; Stephan Schmidt; Mark Rogge; Lawrence J Lesko; Mirjam N Trame
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-08-16

4.  Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats.

Authors:  Maria Teresa Di Martino; Mariamena Arbitrio; Daniele Caracciolo; Francesca Scionti; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Mol Ther Nucleic Acids       Date:  2020-02-08       Impact factor: 8.886

5.  Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221.

Authors:  Maria Teresa Di Martino; Mariamena Arbitrio; Massimiliano Fonsi; Claudio Alberto Erratico; Francesca Scionti; Daniele Caracciolo; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.